cas 150-19-6|| where to buy 3-Methoxyphenol

Nom du produit:3-Methoxyphenol

IUPAC Name:3-methoxyphenol

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM116826-100g	in stock	Ƕȡ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 150-19-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:150-19-6; Formule moléculaire:C7H8O2; Point de fusion:-; Code SMILES:OC1=CC=CC(OC)=C1; Densité:

: Numéro de catalogue:CM116826; Poids moléculaire:124.14; Point d'ébullition:244°C at 760 mmHg; N° Mdl:MFCD00002267; Stockage:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Alcohols; Alcohol is a type of organic compound that carries at least one hydroxyl ( −OH) functional group bound to a saturated carbon atom.

: Fruquintinib; November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.